DrugBiological
Ganitumab clinical trials
Also written AMG 479.
- studies test it
- 28
- open now
- 1
- in phase 3
- 2
- first study started
- 2005
Keep track of what changes. Save the ganitumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AMG 479
- 24
Combined with it in one product
Studies by the year they started
28 studies that test it; most in 2009 (6)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 6 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 6 |
| 2014 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 20
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 12
NantCell, Inc. (9) · NantBioScience, Inc. (3) · National Cancer Institute (NCI) (2) · Amgen (2) · Dana-Farber Cancer Institute (2) · Translational Research in Oncology (2) · M.D. Anderson Cancer Center (2) · Jeffrey Clarke (1)
Often tested with
Tested in the same studies.
Conatumumab (4) · Panitumumab (3) · Everolimus (3) · Rilotumumab (2) · Irinotecan (2) · Capecitabine (1) · Gemcitabine (1) · Doxorubicin (1)
Studies
Open first, then newest update. How each study uses ganitumab is read from its arms, and is right about nine times in ten.
Testing it · 28
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as Ganitumab
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing SarcomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02306161Written as Ganitumab
- Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the PancreasTerminatedPhase 2NantBioScience, Inc.NCT01318642Written as AMG 479
- QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic CancerCompletedPhase 1/2NantCell, Inc.NCT00630552Written as AMG 479
- QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung CancerTerminatedPhase 1/2NantCell, Inc.NCT00807612Written as AMG 479
- QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedPhase 2NantCell, Inc.NCT00626106Written as AMG 479
- QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung CancerTerminatedPhase 1/2NantCell, Inc.NCT00791154Written as AMG 479
- QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid TumorsTerminatedPhase 1/2NantCell, Inc.NCT00819169Written as AMG 479
- Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)CompletedPhase 1/2NantBioScience, Inc.NCT00788957Written as Ganitumab
- Palbociclib + Ganitumab In Ewing SarcomaTerminatedPhase 2Dana-Farber Cancer InstituteNCT04129151Written as Ganitumab
- Study to Evaluate Mechanisms of Acquired Resistance to PanitumumabCompletedPhase 2NantBioScience, Inc.NCT00891930Written as Ganitumab
- QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the PancreasCompletedPhase 3NantCell, Inc.NCT01231347Written as AMG 479
- Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar RhabdomyosarcomaTerminatedPhase 1/2National Cancer Institute (NCI)NCT03041701Written as Ganitumab
- Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)CompletedPhase 2AmgenNCT01327612Written as Ganitumab
- A Study of MEK162 and AMG 479 in Patients With Selected Solid TumorsTerminatedPhase 1/2PfizerNCT01562899Written as AMG 479
- A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007CompletedPhase 1Jeffrey ClarkeNCT01061788Written as AMG 479, Everolimus, Panitumumab
- A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid TumorsTerminatedPhase 1/2Novartis PharmaceuticalsNCT01708161Written as AMG 479
- AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine TumorsCompletedPhase 2Dana-Farber Cancer InstituteNCT01024387Written as AMG 479
- Study of RAD001 + AMG479 for Patients With Advanced Solid TumorsCompletedPhase 1Shadia JalalNCT01122199Written as RAD001 + AMG479
- QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell TumorsCompletedPhase 2NantCell, Inc.NCT00563680Written as AMG 479
See all 28 studies that test ganitumab →
As the comparator · 1 — what is tested is compared with ganitumab
Codes
What other systems call ganitumab · ClinicalTrials.gg INT005541
- MeSH (NLM) C545764ganitumabConfirmed NLM, Wikidata
- UNII (FDA) CK1441RCZ8GANITUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q5521322ganitumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C71531GanitumabOne source FDA
- DrugBank DB12205One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C545764 | ganitumab | Confirmed NLM, Wikidata |
| UNII (FDA) | CK1441RCZ8 | GANITUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5521322 | ganitumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C71531 | Ganitumab | One source FDA |
| DrugBank | DB12205 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.